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cells, LNCaP cells showed increased total levels of LC3-I and LC3-II and no change in p62 in response to C/EBPβ induction (Fig. 3B) . Of note, ectopic C/EBPβ is predominantly expressed as the shorter, dominant inhibitory LIP isoform in LNCaP cells as is endogenous C/EBPβ. Thus induction of CEBPB in LNCaP cells may reduce C/EBPβ trans-activation activity to impair autophagy. As C/EBPβ was shown to directly regulate autophagic genes at the transcriptional level [54, 55] , we also evaluated the expression of several such genes by quantitative real-time PCR (qPCR). We found a modest increase in CTSL, GABARAP, ATG7, BNIP3, BNIP3L and ULK1 mRNAs in PC3 cells and that nearly all of these genes were suppressed upon ectopic C/EBPβ expression in LNCaP cells (Fig. 3C ). These data suggest that the C/EBPβ LIP isoform suppresses autophagy and the C/EBPβ LAP isoform activates autophagy.
C/EBPβ LAP promotes autophagy by augmenting REDD1 expression
Although C/EBPβ is reported to broadly regulate the expression of autophagy genes in the liver [30] , we did not observe differential expression of all genes analyzed in PC3 cells over-expressing C/ EBPβ. Recently, it was shown that REDD1 could promote autophagy by suppressing ATG4b-mediated LC3-II delipidation to LC3-I, an effect most critical during periods of metabolic stress [36] . This function of REDD1 prevents recycling of LC3-II and leads to greater turnover of autophagosomes.
REDD1 can also inhibit mTORC1, which suppresses autophagy by phosphorylating ULK1 and ATG13, upstream autophagy regulators [23] . C/EBPβ was previously shown to cooperate with ATF4 to promote REDD1 transcription by binding to a non-consensus site centered 1,004 bp upstream from the REDD1 transcription start site (TSS), but only in cells under oxidative stress [39, 40] . We evaluated REDD1 gene expression changes in PCa cells expressing shRNA targeting CEBPB by qPCR. In contrast to cells overexpressing C/EBPβ, we found that none of the genes that we had analyzed in Figure 1 were affected by C/EBPβ KD in LNCaP or PC3 cells (Fig. 4A) . However, in PC3 cells with CEBPB deficiency, we found significant 2-fold down-regulation of REDD1 transcript levels ( Fig 4A) . We also found that LNCaP cells showed increased REDD1 upon shCEBPB induction, likely due to decreased expression of the dominant-inhibitory LIP isoform (Fig. 4A) . Notably, REDD1 mRNA showed stronger up-regulation upon C/EBPβ over-expression in PC3 cells than other autophagy genes analyzed (Fig. 4B) . Conversely, over-expression of C/EBPβ in LNCaP cells suppressed REDD1 transcript levels (Fig. 4B ).
As we observed that REDD1 expression correlated with full-length C/EBPβ levels in the absence of oxidative stress, we analyzed the human REDD1 promoter to identify additional binding sites for C/ EBPβ. We found a site matching the C/EBPβ consensus at -603 bp and a near-consensus site at -99 bp.
To test whether C/EBPβ binds to these regions, we subjected nuclear extracts from PC3 cells to chromatin immunoprecipitation (ChIP). Using two different primer pairs, each flanking one of the putative C/EBPβ binding sites, we observed between 6 and 8-fold greater levels of amplified product in extracts precipitated with anti-C/EBPβ antiserum relative to normal rabbit IgG (Fig. 4C ), indicating that endogenous C/EBPβ binds to these regions of the REDD1 promoter.
C/EBPβ regulation of REDD1 suggests that C/EBPβ is not only critical for autophagosome-lysosome fusion, but also might play a role in autophagosome maturation. Residual REDD1 present upon shCEBPB-mediated CEBPB KD must be sufficient to prevent a complete block at this step in autophagy. Knockdown of REDD1 was problematic, as all siRNAs tested also reduced C/EBPβ (not shown), and of note REDD1(-/-) MEFs show greatly reduced autophagosome formation [36] . Therefore, to further test whether C/EBPβ drives early autophagy via REDD1, we transiently over-expressed REDD1 in PC3 cells. We found that expression of REDD1 from the pCMS-EGFP-REDD1 vector [39] increased LC3-II in PC3 cells harboring shNTV, as predicted from its role in early autophagy, but mildly reduced LC3-II in shCEBPB cells, compared to controls expressing the pMax-GFP plasmid (Fig. 4D ).
These results suggest that C/EBPβ promotes autophagy in part by regulating REDD1 expression.
Page ! 10 Previous reports suggest that proteasome inhibitors increase expression and activity of C/EBPβ [27] . As proteasome inhibitors also activate autophagy [42, 56] , we tested whether C/EBPβ is required for autophagy following bortezomib treatment. Gene expression analysis of several autophagy genes revealed that ULK1 and p62 were markedly increased 16 hours after bortezomib treatment of PC3 cells (Fig. 5A ). ATG5 and ATG4B were unchanged and ATG7 and REDD1 were mildly upregulated by bortezomib. The changes in p62 and ULK1 were not mediated by C/EBPβ because shCEBPB cells showed the same increase in gene expression upon bortezomib treatment (Fig. 5B ). Treatment of LNCaP or PC3 cells with bortezomib for 24 hours markedly increased C/EBPβ (LAP), LC3-II, and p62 protein expression (Fig. 5C ). To further evaluate the effects of bortezomib on PCa cell autophagy, we analyzed LC3 and p62 by time course analysis. We found that REDD1 increased from 4-8 hours following 25 nM bortezomib treatment, but then decreased between 8 and 16 hours (Fig. 5D ). LC3-II and p62 protein
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shNTV Bort. levels showed the strongest increase 16 hours after treatment. Lastly, we tested whether C/EBPβ was critical for autophagy following bortezomib exposure. We treated PC3 cells expressing shCEBPB with bortezomib and evaluated autophagy markers by time course analysis. C/EBPβ deficiency decreased REDD1 expression and prevented increases in LC3-II, though shCEBPB cells had higher basal levels of LC3-II (Fig. 5E ). These data indicate that bortezomib promotes autophagy and that C/EBPβ is critical for activating autophagy early after bortezomib treatment.
C/EBPβ LAP promotes prostate cancer survival by augmenting autophagy.
We next evaluated the role of C/EBPβ in regulating prostate cancer survival in response to bortezomib. shNTV and shCEBPB LNCaP cells were seeded in 96-well plates and treated with escalating doses of bortezomib for 48 hours. We evaluated cell viability by WST-1 assay and observed a significant decrease in the IC50 value of cells deficient in C/EBPβ indicating increased sensitivity to bortezomib ( Fig. 6A ). We also evaluated PC3 cells under similar conditions, but did not observe a significant difference in IC50 value ( To evaluate whether autophagy contributed to increased cell death in shCEBPB cells we treated cells with chloroquine (CQ) in combination with bortezomib. Chloroquine is a weak base that accumulates in the acidic compartments of late endosomes and lysosomes, alkalinizes these structures, and subsequently inhibits autophagosome-lysosome fusion [43, 44] . We found that there was no difference in shNTV versus shCEBPB cell death in cultures treated with the combination of CQ and bortezomib, indicating that increased death in shCEBPB cultures was due to a block in autophagy (Fig 6D) . These results demonstrate that C/EBPβ promotes resistance to bortezomib in prostate cancer cells.
C/EBPβ promotes prostate cancer cell growth and sensitivity to bortezomib in vivo.
Next, we generated a pair of TALEN expression vectors with targeting sequences to the human CEBPB gene locus and a donor plasmid containing CEBPB homology arms flanking a neomycin resistance cassette (See Barakat et al., 2016 supplementary figure 1 ). The region between the homology arms within the CEBPB gene contains the TALEN targeting sites. We transfected PC3 cells with these vectors and 48hrs later added neomycin (250µg/ml) to the medium. Cells were incubated for 4 days in neomycin before being split into 96-well plates for neomycin resistant sub-clones. Genomic DNA from several sub-clones were analyzed by PCR with primers designed to amplify the deleted region of CEBPB. We identified one sub-clone which was negative for amplification of this region. However, we were still able to detect C/EBPβ protein in lysates collected from this sub-line (Fig 7a) . A control subline, which was not treated with neomycin and still showed amplification of the CEBPB region by PCR was utilized as control (TALEN control). Subsequent attempts to generate cell lines with complete knockout were unsuccessful. However, these cells with partial loss of C/EBPβ may still be useful for the study of CEBPB in prostate cancer.
We next characterized the growth rates of TALEN and shCEBPB knockdown cells relative to their respective controls. We evaluated cell growth by manually counting cells with a hemacytometer 2 and 4 days after plating and found that suppression of C/EBPβ dramatically decreased the rate of PC3 cell growth by 2.5-fold in shCEBPB and >3-fold in TALEN KD cells (Fig. 7B) . Consistent with this finding, we also evaluated clonogenic growth and observed a decrease in colony number in cultures deficient in C/EBPβ (Fig. 7C ).
Page ! 13 Lastly, we evaluated the role of C/EBPβ in prostate tumor growth and sensitivity to bortezomib.
We subcutaneously engrafted NSG mice with shNTV or shCEBPB PC3 cells in matrigel and when tumor reached sizes between 100 and 300mm 3 mice were placed on a doxycycline-laced animal feed for two days and then received IP injection of bortezomib (1mg/kg) or vehicle (DMSO 1: 5000 in saline) on days 1, 4 and 8. Tumor volume was evaluated by caliper measurement. We found that suppression of C/EBPβ significantly reduced the growth rate of prostate tumors (Fig. 7D) . Significantly, we also found that administration of bortezomib did not significantly affect the growth rate of control shNTV tumors and that suppression of C/EBPβ sensitized these tumors to bortezomib treatment. These results demonstrate that C/EBPβ promotes the growth of castrate-resistant prostate cancer and resistance to bortezomib in vivo.
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C/EBPβ regulates mTOR activity and CRPC progression.
Because we found that C/EBPβ LAP promotes REDD1, a negative regulator of mTOR and AKT activation, we next tested whether altered expression of C/EBPβ could affect mTOR activity. 72 hours after treating shCEBPB PC3 cells with 0.5µg/ml doxycycline, we found that phosphorylated p70S6K
was increased relative to shNTV control cells. Conversely, over-expression of C/EBPβ decreased pp70S6K levels, indicated that mTOR activation was suppressed (Fig. 8A) . Because PC3 cells have predominant LAP expression, the effects of C/EBPβ on mTOR suppression could be attributable to LAP.
We hypothesized that C/EBPβ LIP activates mTOR. We have previously found that the androgen sensitive cell lines LAPC4 and LNCaP exhibited predominant LIP expression and this isoform ratio was maintained after induction of C/EBPβ by anti-androgens bicalutamide and flutamide (Fig 8B) . It has been reported that the anti-androgen enzalutamide can increase the activity of AKT and possibly mTOR [1] . We therefore tested whether C/EBPβ knockdown could repress mTOR activity following enzalutamide treatment in LNCaP PCa cells. Enzalutamide treatment increased 4EBP1 phosphorylation and did not affect p70S6K phosphorylation 72 hours after treatment in shNTV and shCEBPB cells (Fig.   8C ). However, total levels of 4EBP1 increased in shNTV and shCEBPB cells. Unexpectedly, we found that C/EBPβ knockdown had no effect on p70S6K and decreased total levels of 4EBP1. These results suggest that LIP represses cap-dependent translation without affecting mTOR activity.
To determine whether C/EBPβ levels correlate with human prostate cancer progression we interrogated the Oncomine database. In the Grasso et al data set (26) that included gene expression patterns from 28 benign prostate tissues, 59 localized PC, and 35 CRPC samples CEBPB expression was significantly (p=1.9x10-6) elevated in CRPC compared with localized disease (Fig. 8D ). Because C/ EBPβ up regulation was associated with progression to CRPC, we next tested whether C/EBPβ played a role in the development of castrate-resistant growth of PCa tumors in a mouse xenograft model. shNTV or shCEBPB LNCaP cells were subcutaneously engrafted into male NSG mice and when tumors reached a volume between 100 and 300mm 3 animals were put on a doxycycline-laced animal feed and surgically castrated seven days later. Tumor volume was monitored weekly by caliper measurement for 8-weeks (Fig. 8E) . We observed significant suppression of CRPC growth in xenografts expressing shC/ EBPβ (p<0.001). These results suggest that C/EBPβ LIP is a critical determinant of CRPC progression, but does not promote mTOR activity in androgen sensitive cells.
Discussion:
The protein kinase known as mTOR is a key driver of protein synthesis in mammalian cells and is hyper-activated in 40-70% of advanced prostate cancers. Because cancer cells grow at much faster rates than ordinary cells, activation of mTOR is necessary to keep up with metabolic demands of the growing tumor. Androgen deprivation therapy, the primary treatment for advanced prostate cancer, was recently suggested to increase mTOR activity and that this event could drive resistance [1] . The findings of these studies reveal that C/EBPβ translational isoforms can be either beneficial or detrimental to prostate cancer cell survival depending on the treatment type. Our studies in androgen sensitive prostate cancer lines show that these cells preferentially express the LIP isoform and that the isoform ratio is maintained when C/EBPβ protein levels are increased during androgen deprivation. Our findings suggest that the higher levels of LIP are critical for maintaining mTOR activation because when we increase LAP expression, mTOR activity decreases. Further, C/EBPβ expression increases in castrateresistant prostate cancer and suppression of C/EBPβ decreased castrate-resistant prostate cancer tumor Recently, it was demonstrated by two independent groups that under heat-shock stress, cap-independent translation initiation is promoted by N-6-methylation of adenosine (m 6 A) residues in the 5' UTRs of mRNA transcripts via an increase in YTHDF2, an m 6 A "reader" [31, 32] . Interestingly, these groups found that YTHDF2 and HSP70 levels increase beginning at 4 hours following heat shock, which is the same time at which we observe an increase in REDD1 and C/EBPβ protein levels after bortezomib treatment. It is possible that increased m 6 A occurs following bortezomib to drive cap-independent translation and LAP isoform expression.
Although clinical trials investigating bortezomib in PCa patients have produced lackluster results, a recent study suggests that the proteasome may still be a valid target in a subset of prostate cancer patients [35] . In patients younger than 65 with localized cancer, proteasome and protein catabolism genes were shown to be strong predictors of metastatic progression after radical Our results also demonstrate that C/EBPβ further promotes autophagy through direct induction of REDD1 gene expression. Previous reports had shown that C/EBPβ cooperates with ATF4 by binding to adjacent half-sites at -1,004 bp in the REDD1 promoter in cells challenged by oxidative stress [39, 40] . Our ChIP data and over-expression/knockdown studies suggest that C/EBPβ can also bind to a consensus site centered at -603 bp and a near consensus site at -99 bp in the REDD1 proximal promoter in the absence of oxidative stress to induce REDD1 expression. REDD1 indirectly promotes autophagosome turnover by inhibiting LC3-II delipidation and thereby preventing LC3 recycling [36] .
The latter function is consistent with our findings that show decreased LC3-II and p62 levels and increases in core autophagy regulators in PC3 cells over-expressing C/EBPβ. Because REDD1 is not known to directly mediate or control autophagosome-lysosome fusion, it is likely that there are additional genes regulated by C/EBPβ whose protein products promote this function independent of REDD1. And as noted, shCEBPB expression in PC3 cells only reduced REDD1 2-fold, likely allowing autophagosome formation, albeit at a slower rate. However, we were able to partly rescue the defect in autophagy in shCEBPB cells by ectopic expression of REDD1. In particular, LC3-II was not increased by shCEBPB in the presence of exogenous REDD1, suggesting increased flux through autophagy. The latter effect suggests that in the presence of shCEBPB, where autophagosome-lysosome fusion is suppressed, ectopic expression of REDD1 may have positive feedback on the autophagy pathway or additional activities beyond its ability to induce LC3-II.
Proteasome inhibition increases cytosolic and endoplasmic reticulum (ER) protein content and promotes amino acid deprivation [42, 46] . These events activate the amino acid sensitive protein kinase GCN2 and the unfolded protein response in the ER, leading to phosphorylation of eIF2α and suppression of protein translation [45] . Autophagy is thought to promote cell survival in cells treated with proteasome inhibitors by restoring amino acid homeostasis and suppressing ER stress [42] . We found that PCa cells treated with bortezomib show a dynamic regulation of autophagy that was dependent upon C/EBPβ expression. Suppression of autolysosome catabolism has been reported in ovarian and breast cancer cell lines treated with bortezomib, owing to a decrease in cathepsins D and B [48, 49] . The conclusions of these studies are consistent with our findings which showed strong upregulation of p62 and ULK1 but suppression of Cathepsin L (not shown) in PC3 cells treated with bortezomib.
Our research group discovered that treating prostate cancer cells with androgen deprivation therapy increased the levels of C/EBPβ. Because C/EBPβ was shown to regulate mTOR activity via REDD1 expression, we tested whether suppression of C/EBPβ could decrease CRPC growth or progression. Although mTOR activity was altered as expected in PC3 cells, we did not observe the same effect in LNCaP cells. Oddly, suppression of C/EBPβ decreased the total levels of 4EBP1 and had no effect on p70S6K phosphorylation relative to control cells, indicating that LIP suppresses cap-dependent translation by increasing 4EBP1. Interestingly, we found that suppression of C/EBPβ in LNCaP cells delayed castrate-resistant tumor growth in NOG mice. C/EBPβ is reported to bind within androgen receptor occupied regions (ARORs) in distal enhancer sites of AR-regulated genes and repress transcription [33] . Androgen deprivation is reported to drive the progression of high grade-PIN lesions to invasive carcinoma in a PTEN-loss mouse model of PCa and that this progression is driven by MAPK and AKT signaling [34] . Because AR suppresses AKT signaling, it is possible, that derepression of ARregulated genes by loss of C/EBPβ could delay CRPC by decreasing AKT and/or MAPK signaling.
Future investigations into the role of C/EBPβ in CRPC progression could be directed towards its effects on these signaling pathways and it's regulation of AR-regulated genes.
Progress and Accomplishments:
Key progress made during this reporting period included:
• Completion of Major Task 2. Determined that prostate cancer cell lines lacking C/EBPβ showed increased sensitivity to bortezomib.
• Completion of Major Task 3. Determined that C/EBPβ was critical for CRPC growth in ARnegative PC3 cells and for progression to CRPC in LNCaP cells.
Methods
The methods used for these experiments have been described in the attached publication. Barakat et al., 2015 . Statistically significant differences in tumor growth rates were analyzed by linear regression analysis using Graph Pad Prism statistical software.
KEY RESEARCH ACCOMPLISHMENTS:
• Ascertained a critical mechanism regulating C/EBPβ translational isoform expression in PCa cells.
• Determined a critical role for C/EBPβ LAP translational isoforms in promoting PCa cell survival via activation of autophagy.
• Demonstrated for the first time that C/EBPβ promotes progression to CRPC and the growth of AR-negative prostate tumors.
CONCLUSION:
The results of this research project increased our understanding of how the isoforms of C/EBPβ are regulated, how these isoforms could regulate protein catabolic pathways and cellular growth in prostate cancer cells and how altering the levels of individual C/EBPβ isoforms could effect resistance to chemotherapy or anti-androgens. This work highlights the differential role of C/EBPβ translational isoforms in facilitating autophagy and also raises additional questions into the regulatory mechanisms which guide their translation. The findings of these studies identify C/EBPβ isoforms as novel therapeutic targets in PCa progression to CRPC or in promoting acute toxicity to PCa cells in combination with bortezomib. 
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Introduction
Metastatic prostate cancer (PCa) is an incurable disease and a leading cause of cancer death in Europe and North America. When patients acquire resistance to hormonal therapy, second-line chemotherapy is administered, which can increase patient life span by several years. There has been interest in the use of bortezomib, a proteasome inhibitor, for the treatment of PCa, but clinical studies have shown only modest or no significant improvement in patient benefit when administered in combination with hormonal therapy or docetaxel [1] [2] [3] . However, a recent study evaluating microarray data from younger patients (<65 years of age) with localized prostate cancer and treated by radical prostatectomy revealed that gene sets representing proteasome subunits and protein catabolism are the strongest predictors of metastatic progression [4] . Thus, proteasome inhibition may still be of clinical value for certain subsets of patients with PCa.
Autophagy is a catabolic process which serves to turn over longlived proteins and organelles by engulfing them in double-membrane bound vacuoles, autophagosomes. These structures eventually fuse with lysosomes to degrade their contents and recycle lipids, amino acids, and carbohydrates [5] . Autophagy is initiated by activation of a multiprotein type III PI3K complex, composed of Beclin 1, VPS34 and ATG14, which enriches a region of the endoplasmic reticulum (ER) in phosphotidylinositol-3-phosphate to serve as a platform for the recruitment of other proteins to generate an isolation membrane [6, 7] . A group of evolutionary conserved proteins are responsible for elongation and closure of the isolation membrane to form a doublemembrane autophagosome by proteolytic cleavage of LC3 and GABARAP family proteins, covalently linking them to phosphatidylethanolamine (PE) and incorporating them into the burgeoning autophagosome [8, 9] . Autophagy is not only regulated at the initiating steps, as LC3-II can be delipidated by ATG4b to LC3-I to promote LC3 recycling [10] . Conversely, LC3-II delipidation by ATG4b can be suppressed by REDD1, thereby promoting autophagy [11] . Proteins and organelles destined for degradation are trafficked to autophagosomes by the ubiquitinbinding proteins p62 and NBR1 [12] [13] [14] .
Autophagy has been recognized as a central process that cancer cells utilize to adapt to stress brought about by hypoxia, anoikis, radiation, or chemotherapy. Recently, it has been suggested that Abbreviations: bZIP, basic region-leucine zipper; C/EBPβ, CCAAT/enhancer binding protein β; ChIP, chromatin immunoprecipitation; CQ, chloroquine; ER, endoplasmic reticulum; GFP, green fluorescent protein; KD, knockdown; NOD/SCID, non-obese diabetic/severe-combined immuno-deficient; NSG, IL2Rγ −/− ; PE, phosphatidylethanolamine; PCa, prostate cancer; qPCR, quantitative polymerase chain reaction; PB, PiggyBac; mRFP, monomeric red fluorescent protein; shRNA, short hairpin RNA; TSS, transcription start site. * Corresponding author. Contents lists available at ScienceDirect
Cancer Letters j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / c a n l e t autophagy plays a critical role in the resistance of PCa cells to hormonal therapy or chemotherapy and that inhibition of autophagy synergizes with docetaxel or androgen deprivation [15, 16] . Combined treatment of several different cancer cell lines with autophagy suppressive agents and bortezomib increases cell death and improves clinical response in patients with relapsed multiple myeloma [17] [18] [19] . Further, proteasome inhibitor-resistant PCa cells are thought to utilize autophagy to resist this class of drugs [20] . Recently, several groups have shown that autophagy is regulated at the transcriptional level [21, 22] . C/EBPβ, a basic regionleucine zipper (bZIP) transcription factor, was identified as a regulator of circadian autophagy in the liver by inducing a broad array of autophagy genes [23] . C/EBPβ protein is translated from an intronless transcript from three in-frame start codons as higher molecular weight, liver-enriched activating proteins (LAP and LAP*) or the truncated liver-enriched inhibitory protein (LIP). The dominant-inhibitory LIP isoform lacks all three N-terminal activation domain modules and can inhibit transcription by heterodimerizing with LAPs. Another group also showed that C/EBPβ promotes differentiation of 3T3-L1 preadipocytes by activation of ATG4b gene expression and autophagy [24] . Intriguingly, treatment of Burkitt's lymphoma cells with bortezomib dramatically increases the expression of C/EBPβ [25] . Other proteasome inhibitors, such as lactacystin or MG-132, also increase nuclear levels of C/EBPβ and increase its DNA binding [26, 27] . We therefore investigated the role of C/EBPβ in PCa cell autophagy and sensitivity to bortezomib. Our results suggest that autophagy is activated early after bortezomib treatment, that C/EBPβ promotes autophagy in PCa cells via induction of autophagosome-lysosome fusion and via induction of REDD1, and that reducing C/EBPβ expression increases prostate cancer cell sensitivity to bortezomib.
Materials and methods
Cell lines, reagents and mice
PC3 and LNCaP cells were maintained in RPMI media with 10% heat inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT) supplemented with penicillin/ streptomycin. Cells were grown in a humidified incubator maintained at 37°C with 5% CO2. Cell lines transduced with short hairpin RNA (shRNA) or PiggyBac (PB) Teton vectors were grown in media supplemented with 10% tetracycline-screened FBS (Hyclone). For experiments involving inducible expression of shRNA or ectopic C/EBPβ, 0.5 μg/ml doxycycline was added to the media and replaced every 48 hrs. The pCMSeGFP-RTP801 plasmid was purchased from Addgene (Cambridge, MA; plasmid #65057).
Non-obese diabetic/severe-combined immuno-deficient (NOD/SCID); IL2Rγ −/− (NSG) mice were obtained from a breeding colony established in the Johns Hopkins University division of animal resources. The animals were subcutaneously engrafted with 2E06 PC3 cells in PBS in a 1:1 mixture with Matrigel. The animals were monitored daily after transplantation. When tumor volumes reached 100 mm 3 , the mice were placed on doxycycline-laced feed. When tumors reached a volume between 100 and 300 mm 3 , the animals were randomly assigned to receive either DMSO vehicle or bortezomib, by intraperitoneal (IP) injection (1 mg/kg of body weight) on days 1, 4 and 8. The mice were sacrificed 11 days after engraftment. Tumor volumes were determined by caliper measurement using the ellipsoidal formula: length × width × height × 0.5236 [28] .
All animal studies were conducted under protocols approved by the Johns Hopkins Institutional Animal Care and Use Committee in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Western blotting
Protein samples from whole cell lysates or nuclear extracts were prepared and subjected to Western blotting as described [29] . Each experiment was repeated at least twice. Anti-β-actin (AC15) and anti-vinculin (V9131) antibodies were from SigmaAldrich (St. Louis, MO). Anti-C/EBPβ (C-19), anti-C/EBPβ (H-7), and anti-SQSTM1/ p62 (H-290) antibodies were from Santa Cruz Biotechnologies (Dallas, TX). Anti-LC3B (2775), anti-ATG3 (3415), anti-ATG5 (8540), and anti-ATG-7 (8558) antibodies were from Cell Signaling Technologies (Danvers, MA). Anti-REDD1 antibody (10638-1-AP) was from Proteintech (Rosemont, IL).
Quantitative real-time PCR
RNA extraction, cDNA synthesis, and PCR reactions were performed as previously described [29] . Oligonucleotides were designed using PrimerBlast and custom ordered from Sigma-Aldrich. Their sequences are presented in Table 1 .
Ectopic C/EBPβ expression and shRNA
LNCaP cells stably transfected with the TET-on, transposon based PiggyBac vector PB-TRE, or PB-CEBPB expressing murine C/EBPβ, were previously described [29] . PC3 cells were transfected with these same vectors, and cells with stable integration were positively selected with puromycin (2 mg/ml). Lentiviral transduction of PC3 cells with pTRIPZ lentiviral vectors targeting CEBPB was also performed as previously described for LNCaP cells [29] .
TALEN construction and CEBPB gene editing
TALEN DNA constructs targeting the human CEBPB open reading frame (ORF) were constructed as previously described [29] . CEBPB homology arm 1 (HA1) was amplified from 293T DNA with primers TGCtctagaCTGGTGGGAACAATGCCACC and ACTtgatcaTGGTGGCATTGTTCCCACCAG; restriction enzyme sites are in lower case. The resulting fragment was digested with XbaI and SpeI and ligated into the pSEPT donor plasmid [30] . CEBPB homology arm 2 (HA2) was amplified using GCatcgatGAACTTGTTCAAGCAGCTGCC and AGTcagctgAGGCTCCGGAATCTCTTCTC primers. The resulting fragment was digested with ClaI and SalI and ligated into the pSEPT plasmid containing CEBPB HA1. PC3 cells were co-transfected with TALEN expression vectors targeting CEBPB and the pSEPT donor plasmid at a 1:1 ratio and after 48 hours were seeded into a 96-well plate at 1 cell/well with G418. Individual clones were screened for C/EBPβ expression by Western blotting.
Chromatin immunoprecipitation (ChIP)
1E06 PC3 cells were used in each ChIP reaction, using anti-rabbit C/EBPβ antiserum or normal rabbit IgG (Santa Cruz Biotechnology) as previously described [31] . DNA fragments corresponding to the promoter of REDD1 were detected by qPCR using the primers presented in Table 2 .
Cell viability and proliferation assays
To assess cell proliferation, 1E05 PC3 cells were seeded in growth media containing 0.5 μg/ml doxycycline. On days 2 and 4, cells were trypsinized and stained with Trypan blue dye, and viable cells were enumerated using a hemocytometer. Experiments were repeated three times. For clonogenic assays, PC3 cells were trypsinized and seeded into 6-well plates at 200 cells per well. 12 days after plating, cells were fixed and stained with 4% formaldehyde and 0.05% crystal violet. After washing with tap water, colonies were manually counted under a bright field microscope. Clusters of cells containing more than 50 cells were counted as a colony.
Autophagosome-lysosome fusion assay
PC3 cells were plated on 60 mm dishes to obtain 80% confluence on the next day. Cells were transfected with tandem mRFP-GFP fluorescent-tagged LC3 (ptfLC3) (Addgene #21074) [32] . On day two post-transfection, cells were trypsinized and plated on sterile glass bottom dishes (Mattek, Ashland, MA) at a 40-50% confluency. 
the JHU Core Imaging facility. Images were processed using ImageJ software. Cells with predominantly yellow RFP/GFP (autophagosome) or red RFP (autolysosome) punctae were counted and analyzed as described [32] .
Q74-EGFP degradation assay
PC3 cells seeded in 24-well plates were transfected with 500 ng of Q74-EGFP (Addgene #40262) [33] or pMax-GFP (Lonza, Basel, Switzerland). Forty-eight hours after transfection, fluorescent micrographs of GFP-positive cells were taken using a Nikon Ti-E inverted microscope at 400× magnification from at least five nonoverlapping regions of interest. Cells were manually counted using ImageJ software and the percentage of GFP-positive cells displaying punctuate staining was determined.
Statistical analysis
Statistical comparison of the two groups was conducted using Student's t-test. Comparisons of multiple groups were performed using analysis of variance followed by multiple comparisons with Student's t-test and the Holm-Bonferonni correction. P-values were ordered from highest to lowest and α was adjusted to α/(m+1-k) for p(k), where m = number of comparisons and corresponds to the highest p-value. k corresponds to the p-value rank. α was set to 0.05 for comparisons. For analysis of tumor growth, linear regression analysis was used to determine statistical significance in growth rates between groups of mice using Graph Pad Prism statistical software.
Results
C/EBPβ LAP : LIP isoform ratio regulates autophagy in prostate cancer cells
To understand the role of C/EBPβ in prostate cancer cell autophagy, we first ectopically expressed murine C/EBPβ, which shares 98.8% similarity to the human C/EBPβbZIP domain and 80-100% similarity to the human trans-activation and regulatory domains, in the PC3 PCa cell lines using the PB-TRE Tet-on PiggyBac inducible expression vector we had used previously to obtain LNCaP cells harboring doxycycline-inducible C/EBPβ [29] . Induction of PiggyBac-CEBPB (PB-CEBPB) in PC3 cells led to a decline in the total levels of LC3-I and LC3-II and p62 compared to cells expressing the empty PB-TRE vector (Fig. 1A, left) . Decreases in p62 levels typically indicate increased autophagic degradation, while changes in LC3-II can imply blockade or activation of autophagosome formation [34] . We further evaluated other proteins involved in autophagosome nucleation and elongation and found increases in ATG3, ATG5, ATG7 and Beclin-1, suggesting that autophagy is increased upon induction of C/EBPβ (Fig. 1A, right) .
In contrast with these results in PC3 cells, LNCaP cells showed increased total levels of LC3-I and LC3-II, and no change in p62 in response to C/EBPβ induction (Fig. 1B) . Of note, ectopic C/EBPβ is predominantly expressed as the shorter, dominant inhibitory LIP isoform in LNCaP cells as is endogenous C/EBPβ. Thus induction of CEBPB in LNCaP cells may reduce C/EBPβ trans-activation activity to impair autophagy.
As C/EBPβ was shown to directly regulate autophagic genes at the transcriptional level [23, 24, 35] , we also evaluated the expression of several such genes by quantitative real-time PCR (qPCR). We found a modest increase in CTSL, GABARAP, ATG7, BNIP3, BNIP3L and ULK1 mRNAs in PC3 cells and nearly all of these genes were suppressed upon ectopic C/EBPβ expression in LNCaP cells (Fig. 1C) .
C/EBPβ promotes autophagosome-lysosome fusion in PC3 cells
Bafilomycin A1, a vacuolar-ATPase inhibitor, increases lysosomal pH and alters Ca 2+ gradients of the lysosome, subsequently inhibiting fusion with autophagosomes, blocking autophagic flux and leading to accumulation of LC3-I and LC3-II [36, 37] . We treated cells for four hours with bafilomycin A1 and then evaluated lysates by Western blot analysis. Although the total levels of LC3-I and LC3-II were increased in PC3 cells expressing shCEBPB, the ultimate level of LC3-II achieved in response to bafilomycin A1 was not different from the control cells transduced with shNTV ( Fig. 2A, top) . In addition, ectopic expression of C/EBPβ did not enhance autophagic flux in bafilomycin A1-treated cells, as again the peak levels of LC3-II, 4.1 and 3.9, were nearly identical ( Fig. 2A, bottom) . These data suggest that C/EBPβ does not play a dominant role in autophagosome formation, as otherwise CEBPB shRNA might have been predicted to reduce and ectopic C/EBPβ to increase the change in LC3-II in the presence of bafilomycin A1. We next tested whether C/EBPβ regulates turnover of autophagy substrates. We transiently expressed mutant huntingtin-EGFP (Q74-EGFP) fusion protein in PC3 cells together with either shNTV or shCEBPB [33] . Expression of Q74-EGFP results in protein aggregation, which can be observed as punctuate GFP-positive staining. Forty-eight hours after transfection, we quantified the number of GFP-positive cells displaying aggregates and found that there were significantly more cells with GFP aggregates in PC3 cells expressing shRNA targeting CEBPB (Fig. 2B, left and center) . These data indicate that turnover of autophagosomes is augmented by C/EBPβ. In addition, there were significantly more non-viable, Trypan blue dye positive cells in cultures lacking C/EBPβ (Fig. 2B, right) .
The first step in autophagosome turnover is fusion with lysosomes. We therefore next evaluated autophagosome-lysosome fusion in PC3 cells using plasmid ptfLC3, expressing a mRFP-GFP-LC3 fusion protein [32] . As GFP fluorescence is quenched by the acidic environment of the lysosome, yellow punctae visible under fluorescence microscopy, representing signal from both RFP and GFP, indicate autophagosomes, whereas red punctae represent autolysosomes. Doxycycline induction of shRNA from pTRIPZ also induces RFP and so is not amenable to this assay. We therefore utilized TALEN targeting of genomic CEBPB as an alternative means of knockdown (KD). We utilized homologous recombination to insert a neomycin resistance cassette and generate a deletion in the CEBPB locus with a pSEPT donor plasmid containing homology arms of CEBPB flanking the TALEN cut site (Supplementary Figure S1) [30] . We generated a neomycin-resistant subclone which expressed decreased levels of C/EBPβ relative to the control subclone (Fig. 2C) . When TALEN KD cells were transfected with the mRFP-GFP-LC3 reporter, we found that there was a remarkable, 4-fold increase in the percentage of cells with RFP/GFP-positive autophagosomes relative to control cells and a similar decrease in the percent of cells with RFP-positive autolysosomes, implying that fusion with lysosomes is impaired (Fig. 2D) . Collectively, these data demonstrate that C/EBPβ is critical for basal autophagy in PC3 cells by regulating autophagosomelysosome fusion.
C/EBPβ LAP promotes autophagy in PC3 cells by augmenting REDD1 expression
Although C/EBPβ is reported to broadly regulate the expression of autophagy genes in the liver [23] , we did not observe differential expression of all genes analyzed in PC3 cells overexpressing C/EBPβ. Recently, it was shown that REDD1 could promote autophagy by suppressing ATG4b-mediated LC3-II delipidation to LC3-I, an effect most critical during periods of metabolic stress [11] . This function of REDD1 prevents recycling of LC3-II and leads to greater turnover of autophagosomes. REDD1 can also inhibit mTORC1, which suppresses autophagy by phosphorylating ULK1 and ATG13, upstream autophagy regulators [38] . C/EBPβ was previously shown to cooperate with ATF4 to promote REDD1 transcription by binding to a non-consensus site centered 1004 bp upstream from the REDD1 transcription start site (TSS), but only in cells under oxidative stress [39, 40] . We evaluated REDD1 gene expression changes in PCa cells expressing shRNA targeting CEBPB by qPCR. In contrast to cells overexpressing C/EBPβ, we found that none of the genes that we had analyzed in Fig. 1 were affected by C/EBPβ KD in LNCaP or PC3 cells (Fig. 3A) . However, in PC3 cells with CEBPB deficiency, we found a significant 2-fold down-regulation of REDD1 transcript levels (Fig. 3A) . We also found that LNCaP cells showed increased REDD1 upon shCEBPB induction, likely due to decreased expression of the dominant-inhibitory LIP isoform (Fig. 3A) . Notably, REDD1 mRNA showed stronger up-regulation upon C/EBPβ over-expression in PC3 cells than other autophagy genes analyzed (Fig. 3B) . Conversely, overexpression of C/EBPβ in LNCaP cells suppressed REDD1 transcript levels (Fig. 3B) .
As we observed that REDD1 expression correlated with fulllength C/EBPβ levels in the absence of oxidative stress, we analyzed the human REDD1 promoter to identify additional binding sites for C/EBPβ. We found a site matching the C/EBPβ consensus at −603 bp and a near-consensus site at −99 bp (Supplementary Figure S2) . To test whether C/EBPβ binds to these regions, we subjected nuclear extracts from PC3 cells to chromatin immunoprecipitation (ChIP). Using two different primer pairs, each flanking one of the putative C/EBPβ binding sites, we observed between 6 and 8-fold greater levels of amplified product in extracts precipitated with anti-C/ EBPβ antiserum relative to normal rabbit IgG (Fig. 3C ), indicating that endogenous C/EBPβ binds to these regions of the REDD1 promoter.
C/EBPβ regulation of REDD1 suggests that C/EBPβ not only is critical for autophagosome-lysosome fusion, but also might play a role in autophagosome maturation. Residual REDD1 present upon shCEBPB-mediated CEBPB KD must be sufficient to prevent a complete block at this step in autophagy. Knockdown of REDD1 was problematic, as all siRNAs tested also reduced C/EBPβ (not shown), and of note REDD1(−/−) MEFs show greatly reduced autophagosome formation [11] . Therefore, to further test whether C/EBPβ drives early autophagy via REDD1, we transiently over-expressed REDD1 in PC3 cells. We found that expression of REDD1 from the pCMS-EGFP-REDD1 vector [41] increased LC3-II in PC3 cells harboring shNTV, as predicted from its role in early autophagy, but mildly reduced LC3-II in shCEBPB cells, compared to controls expressing the pMax-GFP plasmid (Fig. 3D) . These results suggest that C/EBPβ promotes autophagy in part by regulating REDD1 expression.
C/EBPβ promotes autophagy following bortezomib treatment
Previous reports suggest that proteasome inhibitors increase expression and activity of C/EBPβ [25, 26] . As proteasome inhibitors also activate autophagy [42, 43] , we tested whether C/EBPβ is required for autophagy following bortezomib treatment. Gene expression analysis of several autophagy genes revealed that ULK1 and p62 were markedly increased 16 hours after bortezomib treatment of PC3 cells (Fig. 4A) . ATG5 and ATG4B were unchanged and ATG7 and REDD1 were mildly upregulated by bortezomib. The changes in p62 and ULK1 were not mediated by C/EBPβ because shCEBPB cells showed the same increase in gene expression upon bortezomib treatment (Fig. 4B) . Treatment of LNCaP or PC3 cells with bortezomib for 24 hours markedly increased C/EBPβ (LAP), LC3-II, and p62 protein expression (Fig. 4C) . To further evaluate the effects of bortezomib on PCa cell autophagy, we analyzed LC3 and p62 by time course analysis. We found that REDD1 increased from 4 to 8 hours following 25 nM bortezomib treatment, but then decreased between 8 and 16 hours (Fig. 4D) . LC3-II and p62 protein levels showed the strongest increase 16 hours after treatment. Lastly, we tested whether C/EBPβ was critical for autophagy following bortezomib exposure. We treated PC3 cells expressing shCEBPB with bortezomib and evaluated autophagy markers by time course analysis. C/EBPβ deficiency decreased REDD1 expression and prevented increases in LC3-II, though shCEBPB cells had higher basal levels of LC3-II (Fig. 4E) . These data indicate that bortezomib promotes autophagy and that C/EBPβ is critical for activating autophagy early after bortezomib treatment.
Reduced C/EBPβ slows PC3 tumor growth and increases sensitivity to bortezomib
Autophagy positively regulates "cellular fitness" in a variety of cell types [44] . We therefore evaluated the effect of C/EBPβ on PC3 proliferation. We quantified cell growth over a four day time course and found that inhibition of C/EBPβ by shRNA targeting or TALEN reduced cell accumulation by more than 2-fold (Fig. 5A) . We also evaluated clonogenic growth and found that cells deficient in C/EBPβ due to TALEN targeting or shRNA expression showed a more than two-fold average decrease in colony number (Fig. 5B) . We treated shNTV and shCEBPB PC3 cells with 25 or 50 nM of bortezomib for 24 hours and evaluated viability by Trypan blue dye exclusion. Suppression of C/EBPβ increased cell death relative to shNTV cells by 2-fold with either dose of bortezomib (Fig. 5C, left) . Phase contrast images of cells treated with 50 nM bortezomib and shNTV or shCEBPB are also shown (Fig. 5C, right) . To evaluate whether autophagy contributed to increased cell death in shCEBPB cells, we treated cells with chloroquine (CQ) in combination with bortezomib. Chloroquine is a weak base that accumulates in the acidic compartments of late endosomes and lysosomes, alkalinizes these structures, and subsequently inhibits autophagosome-lysosome fusion [45, 46] . We found that there was no difference in shNTV versus shCEBPB cell death in cultures treated with the combination of CQ and bortezomib, indicating that increased death in shCEBPB cultures was due to a block in autophagy (Fig. 5D) . We next evaluated PC3 tumor growth and sensitivity to bortezomib in vivo. NSG mice subcutaneously engrafted with shNTV or shCEBPB PC3 cells were treated with either vehicle or bortezomib (1 mg/kg) on days 1, 4 and 8 (Fig. 5E) . Consistent with our in vitro findings, we observed a decreased rate of growth of shCEBPB PC3 tumors (p = 0.026). Further, we observed no difference in the rate of growth in control tumors receiving either vehicle or bortezomib. In contrast, bortezomib treatment and CEBPB KD strikingly synergized to further decrease tumor growth (p = 0.017). These results suggest that C/EBPβ is critical for prostate tumor growth and that decreasing C/EBPβ increases sensitivity to bortezomib in vivo.
Discussion
Although clinical trials investigating bortezomib in PCa have produced lackluster results, a recent study suggests that the proteasome may still be a valid target in a subset of prostate cancer patients [4] .
In patients younger than 65 with localized cancer, proteasome and protein catabolism genes were shown to be strong predictors of metastatic progression after radical prostatectomy. Understanding the response of PCa cells to proteasome inhibition is therefore of potential clinical utility.
The results of our study suggest that C/EBPβ regulates fusion of lysosomes and autophagosomes in PCa cells. The effects of C/EBPβ on autophagy were dependent upon the expression ratio of the C/EBPβ translational isoforms, with higher relative levels of LIP : LAP expression suppressing autophagy in LNCaP cells and vice versa in PC3 cells. The observed effect of LIP down-regulating autophagic gene expression is consistent with its role as a transcriptional repressor owing to its lack of N-terminal trans-activation domains. Our data are consistent with previous reports that show a link between C/EBPβ and autophagy. C/EBPβ was reported to control circadian autophagy in mouse liver by broadly activating autophagy gene transcription [23] . Guo and colleagues showed that C/EBPβ activates autophagy by directly regulating ATG4B in 3T3-L1 pre-adipocytes to promote differentiation to mature adipocytes [24] . However, the specific defect in the autophagosome-lysosome fusion that we have revealed in PCa cells is a distinct mechanism from that reported in these earlier studies (Fig. 6) . Analogous to what we have found, however, C/EBPβ(−/−) macrophages exhibit defects in bactericidal activity and fusion of phagosomes with lysosomes [47] . Overall, our findings and those of others show that the effect of C/EBPβ on autophagy is cell type and context specific.
Our results also demonstrate that C/EBPβ further promotes autophagy through direct induction of REDD1 gene expression (Fig. 6) . Previous reports had shown that C/EBPβ cooperates with ATF4 by binding to adjacent half-sites at −1004 bp in the REDD1 promoter in cells challenged by oxidative stress [39, 40] . Our ChIP data and over-expression/knockdown studies suggest that C/EBPβ can also bind to a consensus site centered at −603 bp and a near consensus site at −99 bp in the REDD1 proximal promoter in the absence of oxidative stress to induce REDD1 expression. REDD1 indirectly promotes autophagosome turnover by inhibiting LC3-II delipidation, thereby preventing LC3 recycling [11] . The latter function is consistent with our findings that show decreased LC3-II and p62 levels and increases in core autophagy regulators in PC3 cells overexpressing C/EBPβ. Because REDD1 is not known to directly mediate or control autophagosome-lysosome fusion, it is likely that there are additional genes regulated by C/EBPβ whose protein products promote this function independent of REDD1. And as noted, shCEBPB expression in PC3 cells only reduced REDD1 2-fold, likely allowing autophagosome formation, albeit at a slower rate. However, we were able to partly rescue the defect in autophagy in shCEBPB cells by ectopic expression of REDD1. In particular, LC3-II was not increased by shCEBPB in the presence of exogenous REDD1, suggesting increased flux through autophagy. The latter effect suggests that in the presence of shCEBPB, where autophagosome-lysosome fusion is suppressed, ectopic expression of REDD1 may have a positive feedback on the autophagy pathway or additional activities beyond its ability to induce LC3-II.
During periods of metabolic stress such as exercise, starvation, or hypoxia, REDD1 is critical for autophagosome maturation by inducing LC3-II and regulating proper autophagosome size [11] . REDD1 transcript levels were not increased 16 hrs after 25 nM bortezomib treatment despite elevation of C/EBPβ LAP, indicating that bortezomib interferes with C/EBPβ induction of REDD1 transcription, and protein levels were increased more than two-fold at this time point, suggesting stabilization of REDD1 protein. Consistent with the idea that bortezomib affects REDD1 protein levels independent of C/EBPβ, knockdown of CEBPB did not prevent up-regulation of REDD1 protein by bortezomib, though basal levels were reduced. We also found that LC3-II proteins were up-regulated within 4 hours of bortezomib treatment. However, in cells expressing shCEBPB, LC3-II levels showed only modest changes relative to control cells. These findings suggest that regulation of basal REDD1 transcript and protein levels by C/EBPβ is crucial for LC3B processing early after proteasome inhibitor treatment.
Proteasome inhibition increases cytosolic and endoplasmic reticulum (ER) protein content and promotes amino acid deprivation [42, 48] . These events activate the amino acid sensitive protein kinase GCN2 and the unfolded protein response in the ER, leading to phosphorylation of eIF2α and suppression of protein translation [49] . Autophagy is thought to promote cell survival in cells treated with proteasome inhibitors by restoring amino acid homeostasis and suppressing ER stress [42] . We found that PCa cells treated with bortezomib show a dynamic regulation of autophagy that was dependent upon C/EBPβ expression. Suppression of autolysosome catabolism has been reported in ovarian and breast cancer cell lines treated with bortezomib, owing to a decrease in cathepsins D and B [50, 51] . The conclusions of these studies are consistent with our findings which showed strong up-regulation of p62 and ULK1 but suppression of Cathepsin L (not shown) in PC3 cells treated with bortezomib.
Finally, our findings also show decreased cell and tumor growth rates in PC3 cells lacking C/EBPβ coincident with a decline in basal autophagy. This decline in autophagy could explain the poor growth rates of cells lacking C/EBPβ as autophagy maintains cellular fitness by turnover of damaged organelles and long-lived proteins [44] . We also found that suppression of C/EBPβ increased PC3 cell and tumor susceptibility to bortezomib. Further, CQ did not additively increase PC3 cell death following bortezomib treatment, indicating that bortezomib-induced cell death was related to inhibition of autophagy. These results are in accordance with previous studies wherein combined autophagy and proteasome blockade additively increased tumor cell killing [52] [53] [54] . In particular, our results implicate C/EBPβ as a key mediator of autophagy in PCa and validate The processes associated with transition to castration-resistant prostate cancer (PC) growth are not well understood. Cellular senescence is a stable cell cycle arrest that occurs in response to sublethal stress. It is often overcome in malignant transformation to confer a survival advantage. CCAAT/Enhancer Binding Protein (C/EBP) β function is frequently deregulated in human malignancies and interestingly, androgen-sensitive PC cells express primarily the liver-enriched inhibitory protein isoform. We found that C/EBPβ expression is negatively regulated by androgen receptor (AR) activity and that treatment of androgensensitive cell lines with anti-androgens increases C/EBPβ mRNA and protein levels. Accordingly, we also find that C/EBPβ levels are significantly elevated in primary PC samples from castration-resistant compared with therapy-naive patients. Chromatin immunoprecipitation demonstrated enhanced binding of the AR to the proximal promoter of the CEBPB gene in the presence of dihydroxytestosterone. Upon androgen deprivation, induction of C/EBPβ is facilitated by active transcription as evident by increased histone 3 acetylation at the C/EBPβ promoter. Also, the androgen agonist R1881 suppresses the activity of a CEBPB promoter reporter. Loss of C/EBPβ expression prevents growth arrest following androgen deprivation or anti-androgen challenge. Accordingly, suppression of C/EBPβ under low androgen conditions results in reduced expression of senescence-associated secretory genes, significantly decreased number of cells displaying heterochromatin foci and increased numbers of Ki67-positive cells. Ectopic expression of C/EBPβ caused pronounced morphological changes, reduced PC cell growth and increased the number of senescent LNCaP cells. Lastly, we found that senescence contributes to PC cell survival under androgen deprivation, and C/EBPβ-deficient cells were significantly more susceptible to killing by cytotoxic chemotherapy following androgen deprivation. Our data demonstrate that upregulation of C/EBPβ is critical for complete maintenance of androgen deprivation-induced senescence and that targeting C/EBPβ expression may synergize with anti-androgen or chemotherapy in eradicating PC.
INTRODUCTION
Prostate cancer (PC) is the most prevalent malignancy in adult men in the United States. 1 Although early detection and treatment of localized disease is often curative, PC remains a leading cause of cancer death. Anti-androgen therapy is the most effective approach in patients with advanced disease and induces significant responses in almost all patients. 2 However, androgen deprivation achieved by pharmacologic or surgical castration results in only limited apoptosis of tumor cells 3, 4 and accordingly only partial tumor regression. Indeed, after a period of disease control, most patients develop castration-resistant growth and PC progression, which is responsible for the majority of the morbidity and mortality associated with this disease. 2 Identifying mechanisms that engender castration resistance is crucial for the design of future therapeutic strategies. Progress has been made understanding the mechanisms associated with eventual emergence of castration-resistant PC (CRPC). However, less is known about the early adaptation associated with androgen deprivation. [5] [6] [7] Members of the CCAAT/enhancer binding protein (C/EBP) family of transcription factors are characterized by a conserved C-terminus, which contains both a DNA-binding basic region and leucine-zipper, collectively referred to as the bZIP domain. C/EBPβ is a widely expressed transcription factor that promotes proliferation or terminal differentiation and growth arrest in several different cell types. 8 These opposing functions seem to be regulated by the expression of different C/EBPβ translational isoforms from three in-frame start codons within an intron-less mRNA. 9, 10 The two high molecular weight C/EBPβ isoforms, termed liver-enriched activating proteins (LAP and LAP*), contain N-terminal transactivation domains, whereas the liver-enriched inhibitory protein lacks these transactivation domains. Liverenriched inhibitory protein can dominantly inhibit LAPs and other C/EBP members via heterodimerization or by recruiting transcriptional repressors.
11 C/EBPβ activity affects several facets of PC disease progression. C/EBPβ regulates the expression of steroidogenic genes including StAR and cytochrome p450 aromatase, 12, 13 and its activity is modulated in response to dihydrotestosterone, estrogen and progesterone. [14] [15] [16] [17] It has also been suggested that C/EBPβ can act as a co-repressor of the androgen receptor (AR) in PC. 18, 19 Although C/EBPβ is not detected in healthy prostate, luminal epithelial cells upregulate C/EBPβ in the case of proliferative-inflammatory atrophy, a precursor to PC, 20 and C/EBPβ participates in the regulation of metastatic genes and PC cell survival. 21, 22 However, the contribution of C/EBPβ to the emergence of castration-resistant growth has not been previously investigated. 1 Cellular senescence is a stable cell cycle arrest that occurs in response to a variety of intrinsic and extrinsic sublethal stress stimuli. 23, 24 Accumulating data point to an important role of senescence in cancer progression. 23, 24 Recently, several groups demonstrated that in response to androgen deprivation, PC cells undergo senescence, and that the acquisition of senescence is associated with emergence of castrate-resistant growth. [5] [6] [7] In other lineages, C/EBPβ and its downstream target genes are critical for the induction and maintenance of oncogene-induced senescence, associated with overexpression of activated Ras or BRAF. 8, 25, 26 C/EBPβ can directly bind to target gene promoters and enhancers to induce senescence-associated factors IL-6 and IL-8, but can also suppress E2F-1 target genes and induce growth arrest dependent on E2F:pRb. 8 We now demonstrate that upon androgen deprivation, C/EBPβ is rapidly upregulated in androgen-sensitive PC cells and that AR binds to and suppresses the C/EBPβ proximal promoter. Increased expression of C/EBPβ under these conditions is necessary for acquisition of the senescent phenotype. Accordingly, preventing C/EBPβ upregulation increases the susceptibility of PC cells to apoptosis induced by chemotherapy.
RESULTS
CRPC is associated with increased CEBPB
To determine whether C/EBPβ levels correlate with human PC progression, we interrogated the Oncomine database. 27 In the Grasso et al. 28 data set that included gene expression patterns from 28 benign prostate tissues, 59 localized PC and 35 CRPC samples, CEBPB expression was significantly (Po1.9 × 10 − 6 ) elevated in CRPC compared with localized disease (Figures 1a and b) .
Inhibition of AR induces CEBPB transcription Treatment of LNCaP cells with the synthetic AR agonist R1881 for 24 h results in a dose-dependent 2.5-fold decrease in CEBPB mRNA and protein expression (Figures 2a and b) , and as expected, prostate-specific antigen transcript levels increased under these conditions. Conversely, culturing LNCaP cells in androgendepleted media (ADM) for 7 days resulted in a significant 3.8-fold increase in C/EBPβ expression (Figure 2c ). Pharmacologic inhibition of the AR using bicalutamide resulted in a dosedependent rise in CEBPB transcript abundance, achieving a 7.5-fold increase at the highest dose tested (Figure 2d) . Accordingly, we detected increased protein levels of C/EBPβ in both LNCaP and LAPC4 cells treated with bicalutamide or flutamide ( Figure 2e) . As bicalutamide or flutamide may have an AR agonist effect, we also tested the effect of enzalutamide, which does not have agonistic effects. Similar to bicalutamide, incubation with 20 μM enzalutamide resulted in increased C/EBPβ levels (Figure 2f ).
CEBPB RNA levels were rapidly upregulated within 4 h of exposure of LNCaP cells to bicalutamide (Figure 2g) .
To assess binding of AR to the CEBPB promoter, LNCaP cells were cultured in full media and subjected to chromatin immunoprecipitation analysis. Precipitated DNA was amplified using primers spanning the proximal (−131 to − 242 bp) or distal (−2098 to − 1983 bp) regions of the human CEBPB promoter. We observed AR binding to the proximal but not the distal region (Figure 3a) . Next, CEBPB-luc, containing proximal promoter region (−888 to +64) linked to a luciferase reporter, was co-transfected into LNCaP or DU145 PC cells with CMV-β-galactosidase as internal control. Reproducibly, luciferase activity significantly decreased by 2.5-fold in LNCaP cells cultured with 1 nM R1881 for 24 h compared with vehicle control (Figure 3b ). This effect on CEBPB promoter activation was mediated by the AR as R1881 did not reduce luciferase activity in similarly transfected DU145 cells which lack AR. Treatment of LNCaP cells with bicalutamide for 4 h induced acetylation of histone H3 bound to the CEBPB proximal promoter, whereas culture with dihydrotestosterone suppressed this mark of active transcription (Figure 3c ). Importantly, we did not observe significant changes in the half-life of CEBPB RNA in response to bicalutamide, indicating that the stability of CEBPB transcripts was unaffected (Figure 3d) . Collectively, these results show that the AR suppresses transcription of CEBPB.
Ectopic expression of C/EBPβ suppresses LNCaP cell growth Because C/EBPβ expression was inversely regulated by AR activity, an essential signal for PC cell growth, we next evaluated whether ectopic expression induces growth arrest similar to androgen deprivation. C/EBPβ was inducibly expressed in LNCaP cells using the Tet-regulated transposon-based piggyBac vector 29 and cells with stable integration of the transgene or an empty vector (PB-TRE) control were selected by puromycin (2 mg/ml). Treatment of LNCaP PB-CEBPB cells with doxycycline for 5 days induced an increase in the expression of C/EBPβ 2.5-fold (Figure 4a ), similar to the increase seen in LNCaP cells cultured in enzalutamide. C/EBPβ forced expression was associated with increased levels of the cell cycle inhibitors p16 INK4A and p15 INK4B and a flattened morphology (Figures 4a and b) . Next, we tested the effect of C/EBPβ overexpression on LNCaP cell proliferation. Equal numbers of LNCaP PB-CEBPB or PB-TRE control cells were seeded in doxycycline-containing media and enumerated after 3 and 5 days. Ectopic C/EBPβ expression resulted in a significant 2.3-fold decreased rate of proliferation ( Figure 4c ) and a significantly increased number of Ki67-negative cells 5 days after doxycycline treatment (Figure 4d ) without increased cell death (Figure 4e ). These data demonstrate that elevated levels of C/EBPβ are sufficient to suppress the growth of androgen-sensitive PC cells. C/EBPβ is required for prostate cancer senescence DJ Barakat et al C/EBPβ is required for complete maintenance of androgendeprivation-induced growth arrest Persistence of PC cells under androgen-deprived conditions is an initial step towards development of castration-resistant growth. Upon androgen deprivation, LNCaP cells undergo cell cycle arrest and enter a senescent state. [5] [6] [7] Importantly, androgen deprivationinduced senescence is only partly reversible and cells continue to display senescence markers and poor proliferation after re-exposure to androgen. 6 Because C/EBPβ upregulation was associated with androgen deprivation and its expression sufficient to suppress LNCaP proliferation, we next targeted C/EBPβ to test its function in androgen-deprivation-induced growth arrest. We utilized two independent methods: inducible shRNA and transcription activator-like effector nucleases (TALENs). 30, 31 We designed a pair of TALENs to target the CEBPB gene, transfected LNCaP cells, and screened individual clones for C/EBPβ expression. Subclone 6, was identified as having CEBPB knockdown (presumably due to incomplete targeting of all alleles in the polyploid LNCaP cells) (Figure 5a ), and used in our subsequent experiments. A complete stable deletion of all CEBPB alleles could not be achieved, suggesting C/EBPβ plays a critical role for cell survival. As control we employed subclone 1 in which C/EBPβ expression is similar to that observed in parental cells. In addition, C/EBPβ expression was effectively knocked down in LNCaP cells utilizing a doxycycline-inducible shRNA against CEBPB (shCEBPB) compared with a non-targeting vector control (shNTV) (Figure 5b) . We used flow cytometry to investigate the effect of C/EBPβ depletion on PC cell cycle distribution (Figure 5c ). For these studies, we employed cells expressing the inducible shRNA as stable deletion of C/EBPβ via TALEN required adaptation to low C/EBPβ levels. Cells expressing shCEBPB or shNTV both went into G1 cell cycle arrest when cultured in ADM (Figure 5c ).
The growth arrest induced by androgen deprivation is associated with changes in cell cycle inhibitors including p16 INK4A , p15 INK4B and p21 WAF1 . Because C/EBPβ has been shown to regulate the expression of these genes, we next evaluated their To evaluate whether C/EBPβ is required to maintain growth arrest of LNCaP cells challenged by androgen deprivation, we precultured LNCaP cells harboring shNTV or shC/EBPβ in ADM or ARM with doxycycline for 7 days, re-seeded equal number of cells in ARM and enumerated viable cells 5 days later (Figure 6a ). As expected from the observed inhibition of G1 to S cell cycle progression (Figure 5c ), culture in ADM for 7 days resulted in diminished cell accumulation (not shown). Although in ARM, the rate of proliferation of shCEBPB cells was modestly lower than shNTV cells, C/EBPβ knockdown was associated with a better, although incomplete, recovery of proliferation after pre-culture in ADM (Figure 6b) .
Charcoal-stripped fetal bovine serum (FBS) lacks androgen and multiple other growth factors. To define the specific effect of androgen depletion, LNCaP cells harboring shNTV or shCEBPB were pre-cultured with doxycycline and bicalutamide, enzalutimide or vehicle for 4 days, and subsequently re-plated at equal numbers in ARM without inhibitors (Figure 6a) . In contrast to shNTV cells, which demonstrated twofold decreased recovery, CEBPB-depleted cells completely recovered their proliferation once released from AR inhibition (Figure 6c ). To better reflect recovery and adjust for the different proliferation rate in ARM of shCEBP compared with shNTV cells, we also plotted these data as a ratio of growth of cells pre-cultured in ADM, bicalutamide or enzalutimide to cells pre-cultured in ARM (Figure 6d ). This normalization highlights the recovery of proliferation of shCEBPB compared with shNTV cells in each experiment, indicating that C/EBPβ is required for maintenance of complete growth arrest induced by androgen deprivation and its suppression alleviates the phenotype, at least in part.
C/EBPβ elevation induces senescence Because C/EBPβ seemed to play a role in maintaining growth arrest following androgen deprivation, we next evaluated whether overexpression of C/EBPβ was sufficient to induce senescence in LNCaP cells. Senescent cells are characterized by an increase in cell volume, granularity and lysosomal mass indicated by senescence-associated β-galactosidase (SA-β-gal) activity. 32 Compared with control PB-TRE, PB-CEBPB cells had a significant increase in the number SA-β-gal-positive cells and the level of cell granularity, as assessed by side scatter (Figures 7a and b) . Expression of several secreted gene products is elevated in senescent cells and is referred to as the senescence-associated secretory phenotype. 24 Release of these secreted factors promotes paracrine growth arrest, and C/EBPβ was shown to be central to induction of senescence-associated secretory phenotype genes. 25, 33, 34 Accordingly, overexpression of C/EBPβ led to a significant increase in the transcript levels of two senescenceassociated secretory phenotype-associated genes, IL8 and IGFBP3 (Figure 7c) . Similarly, we observed increased IGFBP3 and IL8 levels upon androgen deprivation, which was abrogated by either CEBPB shRNA or TALEN targeting (Figures 7d and e) . Another feature of senescent cells is accumulation of tightly packed heterochromatin foci characterized by increased di-or trimethylated histone 3 on lysine 9 (H3K9me2, H3K9me3). 35 When cultured in ADM, LNCaPshNTV cells display a twofold increase in the number of heterochromatin foci-positive cells. In contrast, we did not observe an increase in heterochromatin foci in shCEBPB cells cultured under similar conditions (Figure 7f ). Senescent cells exit the cell cycle, and stain negative for Ki67. A similar proportion of shNTV or shCEBPB cells expressed Ki67 in ARM. However, the proportion of Ki67-negative cells after 1 week of culture in ADM was twofold lower in cells lacking C/EBPβ (Figure 7g ). Together, these data indicate that in PC cells C/EBPβ is necessary for induction of senescence upon androgen deprivation. C/EBPβ is required for prostate cancer senescence DJ Barakat et al Cellular senescence engenders a pro-survival phenotype. Given rapid induction of C/EBPβ in the absence of AR signaling and its role in directing senescence, we evaluated whether targeting C/EBPβ synergizes with anti-androgen agents or chemotherapy in killing PC cells. Culture of LNCaP shNTV and shCEBPB in ADM (Figure 8a ) or exposing them to bicalutamide (Figure 8b ) increased the number of dead cells relative to ARM cultures. However, there was no difference in cell viability between shNTV and shCEBPB cells (Figures 8a and b) . However, after pre-culture in ADM, treatment with docetaxel or etoposide induced a significant 68% or 55% increase in cell death, respectively, in LNCaP cells harboring shCEBPB compared with shNTV (Figure 8c) . Together, these data demonstrate that C/EBPβ promotes a pro-survival, drug-resistant phenotype during androgen deprivation.
DISCUSSION
Accumulating evidence points to a strong connection between senescence and tumor progression. 23, 24, 36 Oncogene-induced senescence promotes the eventual emergence of subpopulations of aggressive, malignant cells and thus may be considered a tumor-promoting state. In PC, androgen-deprivation-induced senescence promotes the development of tumor progression and resistance to apoptosis, 5 fostering the emergence of cancerinitiating cells. 37 Increased numbers of senescent cells have been observed in tissue sections from tumors in patients that had been treated with neoadjuvant androgen deprivation therapy. 7 Also, cellular senescence induced by androgen deprivation dramatically increases reactive oxygen species and DNA double-strand breaks, and leads to the outgrowth of hormone-refractory populations in cultured LNCaP cells. 5 CRPC emerges as a result of multiple adaptations, including AR gene amplification, abnormal AR activation or enhanced steroidogenesis. 2 These changes are acquired and propagated as a result of selective pressure exerted on PC cells by an androgen-poor milieu while cells are protected by the androgen-deprivation-induced senescence state. Previous reports have suggested that androgen deprivation leads to a senescent state in both LNCaP and LAPC4 cells, but the mechanism by which these cells become senescent was not well described. [5] [6] [7] Here, we demonstrate that PC cells respond to androgen withdrawal by upregulating CEBPB transcription, that loss of C/EBPβ lead to a reduction in the number of senescent cells following androgen deprivation, and that ectopic expression of C/EBPβ induces the expression of senescent markers indicating that C/EBPβ plays a central role in cellular senescence induced by androgen deprivation, and that impeding the senescent response via inhibition of C/EBPβ expression keeps PC cells susceptible to chemotherapy, validating C/EBPβ as a therapeutic target in androgen-dependent PC.
Probing the Oncomine database revealed elevated expression of CEBPB in human CRPC samples. As CRPC is often characterized by active AR signaling, this finding may seemingly be at odds with our in vitro data showing that AR activity suppresses C/EBPβ expression. Several potential explanations may account for elevated C/EBPβ levels despite active AR signaling in CRPC. It has been demonstrated that there is substantial divergence in AR gene targets when comparing castrate-resistant to androgensensitive cells. 38 Further, androgen deprivation or castration resistance is associated with decreased AR occupancy on repressive DNA elements, 39 and the expression of many ARrepressed genes increases in castrate-resistant cells. 39 Finally, although castrate-resistant cells often exhibit increased levels of AR, AR signaling relative to androgen-sensitive PC cells may not increase because of diminished ligand levels. Therefore, C/EBPβ de-repression may persist in cells that have developed castration resistance.
Our data demonstrate that inhibition of AR leads to rapid upregulation of CEBPB RNA, loss of AR interaction with the CEBPB (e) The number of dead cells on day 5 was assessed by trypan blue exclusion. All graphs represent the average of three experiments, error bars: s.e.m.; *P o0.01; **P o0.02. C/EBPβ is required for prostate cancer senescence DJ Barakat et al promoter and increased promoter H3K acetylation. To our knowledge, this is the first demonstration that CEBPB is a direct AR transcriptional repressive target. This observation is consistent with previous reports showing that AR can inhibit gene expression through interaction with transcriptional co-repressors at proximal promoter regions. [40] [41] [42] Derepression of CEBPB occurs within 4 h of exposure to anti-androgens. Conversely, treatment with AR agonist R1881 results in diminished expression of C/EBPβ and suppression of the activity of a CEBPB promoter luciferase reporter. Accordingly, exposure to dihydrotestosterone leads to a decrease in activating AcH3 histone marks on the promoter. These findings indicate that AR suppresses CEBPB expression directly through regulation of the promoter. Examination of the CEBPB promoter sequence did not identify an androgen response element, suggesting indirect binding of AR. In other contexts, AR directly interacts with Sp1 to regulate gene expression in the absence of an androgen response element making Sp1 a potential mediator of AR regulation of CEBPB. 43, 44 Treatment of LNCaP cells with anti-androgens or culture in hormone-depleted media leads to G1 arrest and cellular senescence. PC cells require AR signaling for transition from G1 to S, and accordingly, we did not observe continued proliferation of cells that had been cultured in hormone-depleted media or with anti-androgens regardless of CEBPB knockdown.
Androgen-deprivation-induced senescence had a profound longlived effect on PC cell proliferation in the presence of normal C/EBPβ levels even after reintroduction of androgens, as previously observed. 6 We found that after androgen deprivation, C/EBPβ deficiency allowed LNCaP cells to resume proliferation when re-seeded in ARM. Thus, C/EBPβ plays an important role in the complete maintenance of senescent growth arrest induced by androgen deprivation.
Senescent cells develop unique secretory paracrine activities, conferring a pro-malignant microenvironment by secreting an array of cytokines and proinflammatory mediators. 24, 45, 46 Our results raise the possibility that C/EBPβ also promotes the expression of senescence-associated secretory genes such as IL-8 and IGFBP3 and the cell cycle inhibitors p21 WAF1 and p15
INK4B
. IL-8 signaling has been shown to promote cell survival, angiogenesis and senescence in pre-clinical models of PC. 8, 47, 48 It activates the PI3K-AKT-mTOR pathway, which is critical for cell survival during androgen deprivation. 49 IGFBP3 is strongly upregulated following androgen deprivation and promotes tumor growth in a mouse PC model. 50, 51 In PC patients, the percentage of cells positive for p15 INK4B was shown to increase with tumor grade. [52] [53] [54] Expression of p21 WAF1 correlates with a worsened prognosis both before and after androgen deprivation therapy, and in vitro studies of p21 WAF1 have shown that it suppresses expression is not essential to androgen-induced senescence, 5 and we see suppression of p16 INK4A in C/EBPβ-deficient LNCaP cells. Overall, C/EBPβ promotes PC senescence and thereby potentially chemo-resistance and progression to castrationresistant growth through multiple transcriptional targets during androgen deprivation therapy (Figure 8d ).
Our delineation of CEBPB upregulation in human hormone-refractory PC further support the concept that C/EBPβ-dependent induction of senescence during androgen blockade promotes castration-resistant progression by providing the opportunity to respond to the selective pressure of anti-androgen therapy. Importantly, these data indicate the potential utility of targeting C/EBPβ in combination with androgen deprivation for novel PC therapy.
MATERIALS AND METHODS
Cell lines and plasmids
LNCaP cells were maintained in RPMI media without phenol red with 10% heat-inactivated FBS (HI-FBS) (Hyclone Laboratories, Logan, UT, USA) supplemented with penicilin/streptomycin. LAPC4 cells were maintained in Iscove's modified Dulbecco's media (IMDM) supplemented with 15% HI-FBS, 1 nM dihydrotestosterone and penicillin/streptomycin. DU145 cells were maintained in RPMI with 10% HI-FBS, and 293T cells were cultured in Dulbecco modified Eagle medium with 10% HI-FBS. Cells were grown in a humidified incubator maintained at 37°C with 5% CO 2 . Cells were split 1:4 and were used until passage 40. Cells transduced with pTRIPZ-shRNA or transfected with pPB-TRE-Puro were maintained in tetracycline-screened FBS (Hyclone Laboratories). For androgen deprivation, cells were cultured in phenol red-free media supplemented with 10% charcoal-stripped FBS (Hyclone Laboratories). AR was blocked using enazlutamide (Selleckchem, Houston, TX, USA) or bicalutamide (Sigma-Aldrich, St Louis, MO, USA).
pTRIPZ-shRNA (Open Biosystems, Lafayette, CO, USA) lentiviral vectors were generated as described 58 and stably transduced cells were selected with puromycin (2 μg/ml) after 48 h. Expression of shRNA was induced by treating cells with 200 ng/ml doxycycline, replaced every 48 h and confirmed by fluorescence microscopy detection of RFP.
The pPB-TRE-Puro plasmid (kindly provided by Jolene Ooi and Pentao Liu) contains a multiple cloning site downstream of a TRE element, and a CAG promoter upstream of rtTA, IRES and apuromycin resistance gene. The mouse Cebpb ORF including the 3′UTR (1-1400) was ligated as BamHI/NotI fragment into the BglII/NotI-digested pPB-TRE-Puro plasmid 29 to generate the pPB-CEBPB which was confirmed by sequencing. Stable PB-TRE and PB-CEBPB cell lines were generated by transfecting equal parts pCMVhyperpiggybase and piggybac vectors by lipofection.
Western blotting
Protein samples from whole-cell lysates and nuclear extracts were prepared and subjected to western blotting as previously described. Quantitative real-time PCR Total RNA was isolated from cells and first strand cDNA was synthesized as previously described. 58 β-actin transcript was used as a reference to normalize samples and relative expression was calculated as described. 58 Each sample was assayed in triplicates and each experiment was repeated at least three times. Oligonucleotides were custom ordered from SigmaAldrich, and their sequences are presented in Table 1 . (f) Expression of an shRNA against CEBPB or non-targeting vector (shNTV) control were induced by doxycycline in LNCaP cells cultured in ARM or ADM. After 7 days, cells were stained for senescence-associated heterochromatin foci (HF) (yellow arrows). Red arrow points to HF-negative cells. Representative photomicrographs are shown (left, × 600 magnification). The average and s.e. of three independent counts is shown (right panel). *P o0.001. (g) Ki67 was quantified using flow cytometry in shNTV or shCEBPB LNCaP cells cultured in ARM or ADM for 7 days and the average proportion of Ki67 negative cells from three experiments is presented. *Po0.01. C/EBPβ is required for prostate cancer senescence DJ Barakat et al TALEN construction and CEBPB gene editing TALEN DNA constructs targeting the human CEBPB ORF were constructed using the Golden Gate Talen assembly kit (Addgene, Cambridge, MA, USA). 30 Targeting sequences were designed using the Cornell University TAL Effector Nucleotide Targeter 2.0 web-based software. Golden Gate assembly of the repeat-variable di-residue sequence was performed according to the manufacturer's instructions, and the completed TALEN pairs were ligated into the pTAL3 vector. The complete TALEN ORF including the repeat-variable and FokI domains was excised using XhoI and ApaI restriction endonuceases and ligated into the pcDNA3.1(+) vector. LNCaP cells cotransfected with TALEN expression vectors targeting CEBPB were seeded in 96-well dishes, and individual clones were screened for C/EBPβ expression by western blotting.
DNA content analysis and flow cytometry
Cell cycle analysis by DNA content was performed as previously described. 60 Ki67-expressing cells were identified by flow cytometry using APC-anti-Ki67 antibody (BioLegend, San Diego, CA, USA). Flow cytometry analysis was performed using a BD FACSCalibur machine (BD Biosciences, San Jose, CA, USA). Sub-cellular debris and dead cells were gated out and singlet discrimination was performed by gating on FL2-A and FL2-W channels and data were interpreted using FloJo Cytometric Analytical software (TreeStar, Ashland, OR, USA).
Chromatin immunoprecipitation 5E6 LNCaP cells were used in each chromatin immunoprecipitation reaction as previously described, 58 using antibodies against C/EBPβ, AR, rabbit IgG (Santa Cruz Biotechnology) or acetylated histone H3 (06-599) (Millipore, Billerica, MA, USA). DNA fragments corresponding to the promoters of interest were detected by PCR using the primers presented in Table 1 .
Cell viability and proliferation assays Viability was determined using the WST-1 assay (Roche, Indianapolis, IN, USA). Briefly, cells were seeded into 96-well plates, allowed to adhere for 48 h and then treated for an additional 48 h. WST-1 reagent (Roche) was directly added to the wells, and after incubation, absorbance was read at 450 nm using a Bio-Rad (Hercules, CA, USA) Microplate Reader Model 680. The 670 nm reference absorbance and readings from blank wells containing only cell culture media and DMSO (vehicle) were subtracted from experimental wells. Relative viability was determined by dividing absorbance readings from vehicle-treated wells. For cell proliferation, LNCaP cells were grown for 7 days in androgen depleted media. Cells were trypsinized, stained with Trypan blue dye and viable cells were enumerated using a hemocytometer. 1.5E5 cells per well were seeded into 6-well plates in ARM. After 5 days, cells were similarly enumerated. TMPRSS2  AATCCCCATCCGGGACAGT  AGGAGTCGCACTCTATCCCA  PSA  GCAGCATTGAACCAGAGGAG  AGAACTGGGGAGGCTTGAGT  ACTB  GACCTGGCTGGCCGGGACCT  GGCCATCTCTTGCTCGAAGT  GAPDH  CCACCCATGGCAAATTCC  GATGGGATTTCCATTGATGACA  CEBPB  AAACTCTCTGCTTCTCCCTCTGC CTGACAGTTACACGTGGGTTGC  IL8  TCTGGCAACCCTAGTCTGCT  GCTTCCACATGTCCTCACAA  BDNF  GCGTGTGTGACAGTATTAGT  CTGGGTAGTTCGGCACTGGG  CGA  GCGGTGGAAGAGCCATCAT  TCTGTGGCTTCACCACTTTTCTC  IGFBP3  GCCAGCGCTACAAAGTTGAC  ATGTGTACACCCCTGGGACT  P16 INK4A  CCGAATAGTTACGGTCGGAGG  CACCAGCGTGTCCAGGAAG  P15 INK4B  GAGGCGCGCGATCCAG  CACCAGCGTGTCCAGGAAG  P21 CIP1/WAF1 ACTCTCAGGGTCGAAAACGG GATGTAGAGCGGGCCTTTGA Abbreviation: ChIP, chromatin immunoprecipitation.
C/EBPβ is required for prostate cancer senescence DJ Barakat et al SA-β-gal chromogenic assay SA-β-gal-positive cells were stained using the chromogenic assay as described. 61 Five random fields of view were imaged on a Leica E600 (Leica, Buffalo Grove, IL, USA) microscope by brightfield microscopy at × 200 magnification. Positive cells were identified as those containing blue precipitate throughout the cytoplasm.
Immunofluorescent staining and heterochromatin foci quantification
LNCaP cells were seeded onto poly-D-lysine-coated glass coverslips and following treatment, were fixed in 4% paraformaldehyde. Cells were washed and incubated in permeabilization buffer (TBS, 2% BSA, 0.5% Triton-X 100, 0.1% sodium azide). After blocking, cells were incubated with anti-di/trimethyl H3K9 (1:250, Cell Signaling Technology, Danvers, MA, USA), washed and incubated with goat anti-mouse-Alexafluor 488-conjugated secondary antibody (Life Technologies). Cells were washed and mounted on glass slides for analysis by fluorescence microscopy. Heterochromatin foci were imaged on a Leica E800 fluorescence microscope with a CCD camera and imaged at × 630 magnification with an oil immersion objective. Fluorescent micrographs of heterochromatin foci from six to seven random fields of view were quantified using ImageJ (National Institutes of Health, Bethesda, MD, USA). Intensely stained nuclei with multiple fluorescent foci that colocalized with DAPI staining were counted as positive cells containing heterochromatin foci.
Statistical analysis
Statistical comparison of two groups of samples was conducted using the Student's t-test. Comparisons of multiple groups of samples was performed using the analysis of variance followed by multiple comparisons with the Student's t-test and the Holm-Bonferonni Correction (α/(n-k+1), where n = number of comparisons and k = rank of P-value).
